Revolution Medicines, Inc. (RVMD) Misses Q4 EPS by 27c, provides guidance

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q4 EPS of ($1.14), $0.27 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $742 thousand versus the consensus estimate of $1.09 million.

GUIDANCE:

Revolution Medicines, Inc. sees FY2024 revenue of $(480)-(520) million, versus the consensus of $6.682 million.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
• JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral